StreetInsider.com News Articles

Form SCHEDULE 13D/A Processa Pharmaceuticals Filed by: Chiliz Group Ltd.

Mon, 23 Feb 2026 11:00:00 -0500

si-local-file:///var/storage/secattach/20260223/26040895.html

Form SCHEDULE 13D/A Processa Pharmaceuticals Filed by: Chiliz Group Ltd.

Mon, 23 Feb 2026 11:00:00 -0500

si-local-file:///var/storage/secattach/20260223/26040895.html

Form 8-K Processa Pharmaceuticals For: Feb 12

Thu, 19 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260219/26029743.html

Form 8-K Processa Pharmaceuticals For: Feb 12

Thu, 19 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260219/26029743.html

Form SCHEDULE 13G/A Processa Pharmaceuticals Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260213/26001443.html

Form SCHEDULE 13G/A Processa Pharmaceuticals Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260213/26001443.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Young David

Wed, 04 Feb 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260204/25948221.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Young David

Wed, 04 Feb 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260204/25948221.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Lin Patrick

Wed, 04 Feb 2026 17:07:00 -0500

si-local-file:///var/storage/secattach/20260204/25948196.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Lin Patrick

Wed, 04 Feb 2026 17:07:00 -0500

si-local-file:///var/storage/secattach/20260204/25948196.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Guy Wendy

Wed, 04 Feb 2026 17:06:00 -0500

si-local-file:///var/storage/secattach/20260204/25948178.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Guy Wendy

Wed, 04 Feb 2026 17:06:00 -0500

si-local-file:///var/storage/secattach/20260204/25948178.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Bigora Sian

Wed, 04 Feb 2026 17:04:00 -0500

si-local-file:///var/storage/secattach/20260204/25948160.html

Form 4 Processa Pharmaceuticals For: Jan 01 Filed by: Bigora Sian

Wed, 04 Feb 2026 17:04:00 -0500

si-local-file:///var/storage/secattach/20260204/25948160.html

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Mon, 12 Jan 2026 09:15:00 -0500

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44^th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.

During the conference, Mr. Ng and Mr. Lin will be available for one-on-one meetings with investors and potential partners to discuss Processa’s clinical pipeline, including the ongoing Phase 2 study evaluating NGC-Cap in patients with advanced

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Mon, 12 Jan 2026 09:15:00 -0500

Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 09 Jan 2026 09:00:00 -0500

ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on the RedChip Small Stocks, Big Money^™ show, a sponsored program on Bloomberg TV this Saturday, January 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

Bruce Ogilvie, Executive Chairman of Alliance Entertainment, appears on the RedChip Small Stocks Big Money^™ show on Bloomberg

Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 09 Jan 2026 09:00:00 -0500

Access the interviews in their entirety at:

Bruce Ogilvie, Executive Chairman of Alliance Entertainment, appears on the RedChip Small Stocks Big Money^™ show on Bloomberg

Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 09 Jan 2026 09:00:00 -0500

Access the interviews in their entirety at:

Bruce Ogilvie, Executive Chairman of Alliance Entertainment, appears on the RedChip Small Stocks Big Money^™ show on Bloomberg

Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 09 Jan 2026 09:00:00 -0500

Access the interviews in their entirety at:

Bruce Ogilvie, Executive Chairman of Alliance Entertainment, appears on the RedChip Small Stocks Big Money^™ show on Bloomberg

Form 8-K Processa Pharmaceuticals For: Jan 06

Wed, 07 Jan 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260107/25817517.html

Form 8-K Processa Pharmaceuticals For: Jan 06

Wed, 07 Jan 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260107/25817517.html

Processa Pharmaceuticals completes enrollment for breast cancer trial

Mon, 05 Jan 2026 09:15:15 -0500

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) announced it has enrolled and dosed 20 patients required for a formal interim analysis in its Phase 2 clinical study of NGC-Cap for advanced or metastatic breast cancer.

NGC-Cap combines the company's proprietary compound PCS6422 with capecitabine. The randomized study compares NGC-Cap against standard capecitabine monotherapy in patients who have received at least one prior cancer treatment, with enrolled patients having a median of two to three prior treatment regimens.

The NGC-Cap treatment involves a single dose of PCS6422 administered one day before capecitabine, followed by capecitabine at 150 mg twice daily for seven days on and

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Mon, 05 Jan 2026 09:15:00 -0500

Interim safety and efficacy data to be reported in Q1

VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer.

“This is an important milestone because it allows us to assess whether NGC-Cap can

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Mon, 05 Jan 2026 09:15:00 -0500

Interim safety and efficacy data to be reported in Q1

“This is an important milestone because it allows us to assess whether NGC-Cap can